FDA records on compounded GLP-1 sellers
Every FDA warning letter and recall report naming compounded or unapproved semaglutide, tirzepatide and related drugs, company by company, with links to the originals.
Records updated Nov 15, 2026
155
FDA warning letters
Letters whose text names semaglutide, tirzepatide, retatrutide, liraglutide or cagrilintide sold outside FDA approval. FDA issued 75 of them in 2026.
108
Telehealth companies warned
Companies FDA describes as telehealth companies in the subject line of a GLP-1 warning letter, across 111 letters.
81
Recall reports
openFDA recall reports for compounded or unapproved GLP-1 products from 17 firms. The most common reason FDA recorded is “Lack of assurance of sterility.”
15
Letters citing research-use labeling
Warning letters that quote “research use,” “for research purposes” or “not for human consumption” labeling on GLP-1 products.
Latest FDA warning letters
| Later letters FDA lists | Letter | ||||
|---|---|---|---|---|---|
| Oct 30, 2026 | RonanRx, Inc. dba RonanRx | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 24, 2026 | Cheap Medicine Shop/www.cheapmedicineshop.com | Unapproved New Drugs/Misbranded (Internet Pharmacy) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 23, 2026 | Online Generic Medicine/www.onlinegenericmedicine.com | Unapproved New Drug/Misbranded (Internet Pharmacy) | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Sep 18, 2026 | Empower Clinic Services, LLC dba Empower Pharmacy | CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | TXP Innovations LLC dba Tex Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Royal Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | NuScience Peptides LLC | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide, Survodutide, Mazdutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peptide Partners LLC | Unapproved New Drugs/Misbranded | Semaglutide, Tirzepatide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Aug 24, 2026 | Peak Performance Peptides | Unapproved New Drugs/Misbranded | Semaglutide, Retatrutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
| Jun 8, 2026 | Maximus Health, Inc. dba Maximus | False & Misleading Claims/Misbranded (Telehealth) | Semaglutide, Tirzepatide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
Browse
- All 161 companies, or the A to Z list
- By drug: Semaglutide, Tirzepatide, Retatrutide, Liraglutide, Cagrilintide
- FDA-registered 503B outsourcing facilities, each with its inspection history
- FDA compounding pharmacy inspections, Form 483s and warning letters
- GLP-1 listings in FDA’s NDC Directory: outsourcing facility compounded products and bulk ingredients, with FDA’s marketing category
- Medicare and Medicaid spending on GLP-1 drugs, from CMS data, by brand, year and state
- Justice Department and state attorney general actions against GLP-1 sellers
- October 2026 report and all monthly reports
- Download the data (CSV, free to reuse)
Questions answered from the records
- Has the FDA issued warning letters to GLP-1 telehealth companies?
- How many FDA warning letters about compounded semaglutide were issued in 2026?
- Is compounded semaglutide still legal after the FDA shortage ended? FDA’s dated statements
- Is compounded tirzepatide still legal to buy online in 2026? FDA’s dated statements
- Why is the FDA cracking down on compounded GLP-1 drugs? What its letters and statements cite
- Is it legal to buy semaglutide labeled “research use only”? FDA’s statements and warning letters
- Which compounded semaglutide products have been recalled?
- How many FDA adverse event reports involve compounded semaglutide?
- How many FDA adverse event reports involve compounded tirzepatide?
- How many FDA adverse event reports for semaglutide, tirzepatide and liraglutide are marked serious?
- Which reactions are listed most often in FDA adverse event reports for semaglutide and tirzepatide?
- Is semaglutide still on the FDA drug shortage list?
- Is tirzepatide still on the FDA drug shortage list?
- GLP-1 telehealth brands and websites named in FDA warning letters
- How to check a GLP-1 telehealth company’s FDA record
- How to check a compounding pharmacy making semaglutide: its FDA and state records
- How do I check if a pharmacy is registered as an FDA 503B outsourcing facility?
- How do I find FDA warning letters for a compounding pharmacy?
- What is the difference between a 503A pharmacy and a 503B outsourcing facility for semaglutide?
- 503B outsourcing facilities and semaglutide: registration, inspection and GLP-1 records
- Has the FDA inspected Empower Pharmacy? Inspection and warning letter records
- Has Olympia Pharmacy had FDA inspection findings? Form 483 and letter records
- Is Strive Pharmacy a registered 503B outsourcing facility?
- How many FDA-listed compounding pharmacies hold a state pharmacy license in Texas, California, Florida, Illinois, Colorado and Connecticut?
- Which 503B outsourcing facilities had FDA inspections classified Official Action Indicated?
- Where does compounded semaglutide API come from? FDA import records by country
- What is FDA’s GLP-1 API Green List (Import Alert 66-80)?
- How many GLP-1 import shipments has FDA refused, and from which countries?
- Most common Form 483 observations at 503B outsourcing facilities
- What is an FDA Form 483?
- Which outsourcing facilities list compounded semaglutide or tirzepatide with FDA?
- Is a listed NDC number the same as FDA approval? FDA’s own words
- How much did Medicare Part D spend on Ozempic in 2024?
- How much has Medicare Part D spending on GLP-1 drugs grown since 2020?
- How much does Medicaid spend on GLP-1 drugs in each state?
- Which companies list bulk semaglutide or tirzepatide ingredient with FDA?
- Have state attorneys general taken action against GLP-1 weight loss clinics and online sellers?
- Has the Justice Department brought cases over illegal semaglutide or tirzepatide sales?
- Which companies did FDA warn for selling semaglutide online?
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.